If you or a loved one has gallbladder or bile duct cancer, you may be interested in learning more about treatments for it. For a long time, the standard treatment options for this cancer type were ...
Zanidatamab-hrii received FDA accelerated approval for HER2-positive biliary tract cancer, showing a 52% objective response rate in the HERIZON-BTC-01 trial. Biliary tract cancers represent 3% of ...
Submission based on data from Phase 2b HERIZON-BTC-01 trial, which met its primary endpoint in patients receiving zanidatamab for previously treated HER2-positive biliary tract cancer (BTC) ...
Please provide your email address to receive an email when new articles are posted on . The FDA granted accelerated approval to zanidatamab-hrii for treatment of adults with previously treated ...
At its April 2025 meeting, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) gave a conditional marketing authorization for Ziihera (zanidatamab, Jazz ...
Nov 20 (Reuters) - The U.S. Food and Drug Administration approved Jazz Pharmaceuticals' (JAZZ.O), opens new tab drug for the treatment of a type of biliary tract cancer, the company said on Wednesday.
Organ-specific responses to nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma: A multicenter, retrospective study. This is an ASCO Meeting Abstract from the 2025 ASCO ...
Compass Therapeutics (CMPX) is advancing antibody-based oncology therapies, with lead asset tovecimig targeting significant unmet needs in biliary tract cancer (BTC). Tovecimig achieved a 17% ORR in ...
"Future guidelines panels could review these results and consider recommending the inclusion of immunotherapy with chemotherapy for the first-line treatment of advanced biliary tract cancer in the ...
Tovecimig combined with paclitaxel showed a 17.1% response rate in biliary tract cancer, outperforming paclitaxel alone. The COMPANION-002 study reported lower progressive disease rates with tovecimig ...
ctDNA is a valuable prognostic biomarker for relapse in early-stage BTC, outperforming carbohydrate antigen 19-9 levels. ctDNA monitoring can detect molecular recurrence earlier than standard ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results